Icelanders' DNA Helps Map Disease
REYKJAVIK, Iceland-Pharmaceutical company Hoffman-La Roche will try to develop a schizophrenia drug based on information from the Icelandic gene pool.
A research project done by deCODE genetics in Iceland has been using the entire Icelandic population as a study subject. Kari Stefansson, deCODE CEO, said the majority of the country's 270,000 people have been included in the DNA database.
Roche agreed to pay the company $200 million for information gathered from the country's DNA. Since the deal was signed in February 1998, deCode has found genes related to eight different diseases.
The schizophrenia gene encodes a protein that appears to be involved with the disease itself. Another protein that interacts with the one made by the gene may also provide a target for a drug.
Schizophrenia affects 1% of the global population and usually appears during adolescence or young adulthood. Drugs can currently control hallucinations, delusions, and emotional disturbances caused by the disease.
Information from www.arizonarepublic.com
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
